Vanillin oxime inhibits lung cancer cell proliferation and activates apoptosis through JNK/ERK-CHOP pathway

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Lung cancer remains a leading cause of cancer-related deaths globally.
• There is a continuous need for novel therapeutic agents to combat lung cancer.
• Vanillin oxime, a vanillin derivative, presents a potential candidate for investigation.

Purpose of the Study:

• To investigate the anti-cancer effects of vanillin oxime on lung cancer cells.
• To explore the underlying molecular mechanisms of vanillin oxime-induced cell death.
• To evaluate the potential of vanillin oxime as a therapeutic agent for lung cancer.

Main Methods:

• Cell viability was assessed using MTT assay.
• Apoptosis was detected by flow cytometry.
• Gene and protein expression levels of apoptosis-related molecules (Bax, Bcl-2, caspase-3, -9, CHOP, DR5) were analyzed by RT-PCR and Western blotting.
• Levels of phosphorylated extracellular-signal-regulated kinase and c-Jun N-terminal kinase were measured.

Main Results:

• Vanillin oxime suppressed lung cancer cell viability in a dose-dependent manner.
• It induced apoptosis in A549 and NCI-H2170 cells.
• Vanillin oxime modulated the expression of pro-apoptotic (Bax, caspase-3, -9) and anti-apoptotic (Bcl-2, survivin, Bcl-xL, cFLIP, IAPs) proteins.
• It significantly elevated the expression of DR4, DR5, CHOP, and phosphorylated ERK and JNK.
• Apoptosis was mediated through the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway.

Conclusions:

• Vanillin oxime exhibits significant anti-proliferative and pro-apoptotic effects on lung cancer cells.
• The mechanism involves the induction of apoptosis via the TRAIL-mediated pathway.
• Vanillin oxime holds promise as a potential therapeutic agent for lung cancer and warrants further investigation.